Articles related to SCHIZOPHRENIA

The FDA has approved once-monthly subcutaneous olanzapine for adults with schizophrenia, supported by placebo-controlled trial data showing symptom improvement and sustained efficacy through 48 weeks, while eliminating several logistical requirements associated with treatment initiation.

A post hoc analysis of five brexpiprazole trials found improved functioning in adults with schizophrenia, including those with baseline hostility or agitation. The exploratory findings require interpretation alongside trial-design limitations and lack of multiplicity adjustment.

Viral claims described the ketogenic diet as a cure for schizophrenia despite limited supporting evidence. Available research consists of small pilot studies, while established treatment approaches continue to rely on pharmacologic and psychosocial interventions.

A narrative review and accompanying expert commentary outlined diagnostic features distinguishing substance-induced psychosis from primary psychotic disorders amid rising cannabis and stimulant exposure.

The Tardive Dyskinesia Impact Scale showed high discrimination and precision across physical function and socioemotional domains in pooled data from 388 patients in the KINECT 3 and KINECT 4 valbenazine trials.

A J Clin Psychiatry commentary proposes a risk-benefit matrix favoring empiric catatonia treatment when diagnostic uncertainty exists, citing the syndrome’s high morbidity and the effectiveness of available interventions.